- Lois et règlements
- eservices
-
Media Center
Hotline for Health Services for Displaced Lebanese 1787Hotline for the Patient Admission to Hospitals 01/832700COVID-19 Vaccine Registration Form covax.moph.gov.lbMoPH Hotline 1214
Are you a new member? Sign up now
close
SULIQUA - - 3x3ml
| ATC | B/G | Ingredients | code | Registration Nb | brand_name | Dosage | Presentation | Form | Route | Agent | Laboratory | man_country | Price | Pharmacist Margin | Startum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A10AE54 | BioTech | Insulin glargine - 100IU/ml, Lixisenatide - 33mcg/ml | 10559 | 160420/1 | SULIQUA | 3x3ml | Injectable solution | SC | Mersaco | Sanofi Aventis Deutschland GmbH | Germany | 7,975,793 L.L | 21.26 | C | Sanofi Aventis (Suisse) SA | Switzerland | 2/5/2024 | 0 |